LentiGlobin Shows Positive Effects in Severe Sickle Cell Disease Patients, Phase 1/2 Data Reports.
BY ALEJANDRA VIVIESCAS, PHD Bluebirdbio.com presented new positive results from the ongoing Phase 1/2 HGB-206 clinical trial evaluating the effectiveness and safety of investigational gene therapy LentiGlobin in patients with severe sickle cell anemia. The company had previously revealed findings from the trial at the end of last year...
Recent Comments